Russian Heart Failure Journal 2008year Treatment of hypereosinophilic syndrome


To access this material please log in or register

Register Authorize
2008/

Treatment of hypereosinophilic syndrome

Gendlin G.E., Lepkov S.V.

Keywords:

DOI:

    1.    Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83 (10):2759–2779.
    2.    Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994;121 (9):648–653.
    3.    Klion AD, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117 (6):1292–1302.
    4.    Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348 (13):1201–1214.
    5.    Gotlib J, Cools J, Malone JM 3rd et al. The FIP1L1‑PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103 (8):2879–2891.
    6.    Klion AD, Robyn J, Akin C et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103 (2):473–478.
    7.    Gleich GJ, Leiferman KM, Pardanani A et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359 (9317):1577–1578.
    8.    Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Clinical and molecular features of FIP1L1‑PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18 (4):734–742.
    9.    Jovanovic JV, Score J, Waghorn K et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1‑PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109 (11):4635–4640.
    10.    Pardanani A, Reeder T, Porrata LF et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101 (9):3391–3397.
    11.    Pitini V, Arrigo C, Azzarello D et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood. 2003;102 (9):3456–3457.
    12.    Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12 (8):908–916.
    13.    von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1‑PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia. 2005;19 (2):286–287.
    14.    Lierman E, Folens C, Stover EH et al. Sorafenib is a potent inhibitor of FIP1L1‑PDGFRalpha and the imatinib-resistant FIP1L1‑PDGFRalpha T674I mutant. Blood. 2006;108 (4):1374–1376.
    15.    Topol EJ, Textbook of Cardiovascular Medicine, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2002.
    16.    Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th edition. Elsevier, Philadelphia, PA, 2007.  

To access this material please log in or register

Register Authorize
Ru En